Synonyms that are in the dictionary are marked in green. Synonyms that are not in the dictionary are marked in red.
Antonyms that are in the dictionary are marked in green. Antonyms that are not in the dictionary are marked in red.
Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.
Source: https://www.etfdailynews.com/2023/08/09/barclays-trims-arvinas-nasdaqarvn-target-price-to-39-00/
BlackRock Inc. increased its stake in Arvinas by 0.9% during the 3rd quarter.
EcoR1 Capital LLC raised its stake in shares of Arvinas by 19.0% during the first quarter.
Source: https://www.etfdailynews.com/2023/10/28/arvinas-nasdaqarvn-price-target-cut-to-26-00/
Finally, Price T Rowe Associates Inc. MD grew its holdings in Arvinas by 8.6% during the 4th quarter.
Source: https://www.etfdailynews.com/2023/10/28/arvinas-nasdaqarvn-price-target-cut-to-26-00/
Oppenheimer decreased their price objective on shares of Arvinas from $102.00 to $95.00 in a research report on Tuesday, January 10th.
Source: https://www.etfdailynews.com/2023/02/26/hc-wainwright-reiterates-buy-rating-for-arvinas-nasdaqarvn/
Pathstone Family Office LLC purchased a new stake in Arvinas in the fourth quarter valued at approximately $207,000.
Tower Research Capital LLC TRC grew its stake in shares of Arvinas by 57.4% in the first quarter.
Truist Financial decreased their price target on shares of Arvinas from $100.00 to $65.00 and set a “buy” rating for the company in a research note on Tuesday, January 17th.
Wedbush decreased their price objective on shares of Arvinas from $43.00 to $27.00 in a research report on Tuesday, January 10th.
Source: https://www.etfdailynews.com/2023/02/26/hc-wainwright-reiterates-buy-rating-for-arvinas-nasdaqarvn/